Krystal Biotech, Inc.

Krystal Biotech announced positive clinical data from its Gorlin Syndrome Pilot Study evaluating KB113 for basal cell carcinomas. The study showed over 80% of assessed lesions regressed, including non-injected lesions, indicating a potential abscopal effect. All injected lesions achieved complete clearance histologically. KB113 was well-tolerated with mild, transient adverse events. The company is discussing further clinical development with the FDA.

Krystal Biotech, Inc. reported strong financial results for the second quarter and first half of 2026, driven by increased product revenue from VYJUVEK. Product revenue for Q2 2026 grew 24.1% year-over-year to $119.2 million, leading to a 42.9% increase in net income to $54.8 million and diluted EPS of $1.79. The company maintains a robust liquidity position with $845.6 million in cash and short-term investments, which is expected to fund operations for at least the next 12 months. The filing also noted ongoing legal proceedings, including a DOJ subpoena and a patent inventorship lawsuit.

Krystal Biotech reported strong financial results for Q2 2026, with global VYJUVEK net product revenue reaching $119.2 million, a 24% increase year-over-year, and net income of $54.8 million. The company maintains a robust balance sheet with $1.1 billion in cash and investments. Krystal Biotech is on track for VYJUVEK launches in Spain and Italy later this year and anticipates multiple clinical data readouts in the second half of 2026 across its pipeline.

Krystal Biotech, Inc. announced it will report its second quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open. The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss the financial results and provide a business update. A replay of the webcast will be available for at least 30 days on the company's website.

Krystal Biotech, Inc. filed a response to a U.S. Patent and Trademark Office action regarding its investigational gene therapy KB801 for neurotrophic keratitis. The response included previously undisclosed data from a single patient in a discontinued clinical study, showing complete closure of a persistent corneal epithelial defect. The company clarified that the study was discontinued to advance KB801 to a pivotal trial, with no safety concerns observed. This disclosure ensures equal access to information becoming public through the patent prosecution record, with the company emphasizing that this single-patient observation does not represent top-line results or allow conclusions on safety or efficacy.

Krystal Biotech reported strong financial results for the first quarter of 2026, with VYJUVEK net product revenue reaching $116.4 million, a 32% increase from the prior year, and a net income of $55.9 million. The company also announced significant progress in its pipeline, including the completion of enrollment for the KB803 registrational study and anticipated data readouts for KB803 and KB801 in 2026. Additionally, the FDA granted platform technology designation for KB407 and KB111, potentially accelerating future development, and the company maintains a robust balance sheet with $1.0 billion in cash and investments.

Krystal Biotech, Inc. announced it will release its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets. The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss the financial results and provide a business update. Investors and the public can access the live webcast or a replay on the company's website.